Comparative Pharmacology
Head-to-head clinical analysis: HALOTEX versus MYIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTEX versus MYIDYL.
HALOTEX vs MYIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
50 mg orally twice daily without regard to meals.
None Documented
None Documented
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Category C
Category C
Antifungal
Antifungal